Prostate Cell News 9.47 December 7, 2018 | |
| |
TOP STORYFOXA1 down-regulation induced TGF-β signaling, epithelial-mesenchymal transition, and cell motility, which was effectively blocked by TGF-β receptor I inhibitor galunisertib (LY2157299). Combinatorial LY2157299 treatment sensitized prostate cells to enzalutamide, leading to synergistic effects in inhibiting cell invasion in vitro and xenograft castration resistant prostate cancer tumor growth and metastasis in vivo. [J Clin Invest] Abstract | Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)NSD2 Is a Conserved Driver of Metastatic Prostate Cancer Progression Scientists elucidated cell-intrinsic drivers of metastatic prostate cancer progression through analyses of genetically engineered mouse models and correlative studies of human prostate cancer. In particular, nuclear receptor binding SET Domain Protein 2 (NSD2) was robustly expressed in lethal prostate cancer in humans, while its silencing inhibited metastasis of mouse allografts in vivo. [Nat Commun] Full Article | Press Release The authors showed that a amotl1-derived circRNA, termed circAMOTL1L, was downregulated in human prostate cancer (PCa), and that decreased circAMOTL1L facilitated PCa cell migration and invasion through downregulating E-cadherin and upregulating vimentin, thus leading to EMT and PCa progression. [Oncogene] Full Article Genome-Wide CRISPR Screens Reveal Synthetic Lethality of RNASEH2 Deficiency and ATR Inhibition Scientists demonstrated that RNASEH2 deficiency is synthetic lethal with ataxia telangiectasia mutated and RAD3 related (ATR) inhibition both in vitro and in vivo. RNASEH2-deficient cells exhibited elevated levels of DNA damage and, when treated with AZD6738, underwent apoptosis or senescence. [Oncogene] Abstract Androgen treatment suppressed PDCD4 expression in a dose-responsive and miR-21-dependent manner. PDCD4 knockdown enhanced androgen-dependent cell proliferation and cell cycle progression, inhibited apoptosis, and was sufficient to drive androgen-independent growth. [Mol Cancer Res] Abstract Researchers describe the establishment and characterization of an AR+, PSMA+, ERG+, PTEN−/−, CHD1+/− patient-derived xenograft model termed ‘C5’, which has been developed from a 60 years old patient suffering from castration-resistant prostate cancer. [Sci Rep] Full Article Normal epithelial prostate RWPE-1 cells and PCa PC-3 cells were infected with polyomavirus BK for 21 days. Cell proliferation, cytokine production, adhesion, invasion ability, and epithelial-to-mesenchymal transition markers were analyzed. [J Cell Physiol] Abstract BCAR4 Activates GLI2 Signaling in Prostate Cancer to Contribute to Castration Resistance Overexpression of breast-cancer anti-estrogen resistance 4 (BCAR4) in PC346 cells increased cell growth and migration, but turned the cells insensitive to androgen. On the other hand, growth and migration of androgen receptor-negative DU145 cells are insensitive to androgen, while depletion of BCAR4 in DU145 cells not only decreased cell growth, but also turned the cells sensitive again to androgen. [Aging (Albany NY)] Full Article KLF2 Inhibits the Migration and Invasion of Prostate Cancer Cells by Downregulating MMP2 Scientists identified that Kruppel-like factor 2 (KLF2) was downregulated both in prostate cancer (PCa) clinical tissue samples and in cancer cell lines. The overexpression of KLF2 inhibited the migration and invasion of PCa cells via the suppression of MMP2. [Am J Mens Health] Full Article Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSOligometastatic Prostate Cancer: Reality or Figment of Imagination In the long term, refinement of the oligometastatic case definition likely will require biologic risk-stratification schemes. To determine optimal treatment strategies and identify patients most likely to benefit from metastasis-directed therapy, future efforts should focus on conducting high-quality, prospective trials with much-needed molecular correlative studies. [Cancer] Full Article Forkhead Box O4 Transcription Factor in Human Neoplasms: Cannot Afford to Lose the Novel Suppressor The authors present the clinical and pathological significance of forkhead box O4 (FOXO4) in human cancer. Additionally, the potential clinical applications of future FOXO4 research are discussed. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSGenomic Health, Inc. announced they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic version of the Oncotype DX® Genomic Prostate Score® test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world. [Genomic Health, Inc.] Press Release Progenics Pharmaceuticals, Inc. announced that the first patient has been dosed in the company’s Phase III CONDOR study evaluating the diagnostic performance and clinical impact of PyLTM in men with biochemical recurrence of prostate cancer. [Progenics Pharmaceuticals, Inc.] Press Release Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression Veru Inc. announced that the company has dosed its first patient for its bioequivalence study of Tadalafil and Finasteride combination tablet for benign prostatic hyperplasia (BPH). The bioequivalence study will enroll 36 patients and will be completed in approximately four weeks. [Veru Inc.] Press Release OncBioMune Pharmaceuticals, Inc. provided an update on the Phase II clinical trial of ProscaVax being hosted at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard University. OncBioMune has confirmed that a site visit is scheduled for December 19, 2018. This is the check-off meeting before beginning enrollment in the clinical trial, which is expected to transpire in the coming weeks. [OncBioMune Pharmaceuticals Inc.] Press Release | |
| |
POLICY NEWSResearch Funders Make Secretive Overseas Investments: Report An investigation by Science reveals that charities’ investments support activities opposed to their own missions, such as human health and environmental protection. [The Scientist] Editorial China Backs Bold Plan to Tear Down Journal Paywalls In a huge boost to the open-access movement, librarians and funders in China have said that they intend to make results of publicly funded research free to read immediately on publication. The move includes a pledge of support for Plan S, a bold initiative launched in September by a group of European funders to ensure that, by 2020, their scientists make papers immediately open. [Nature News] Editorial
| |
EVENTSNEW Genitourinay Cancers Symposium Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Associate – Prostate Cancer (Baylor College of Medicine) Tenure-Track/Tenured Faculty Position – Cancer Biology (University of Chicago) Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine) Postdoctoral Fellow – Advanced Prostate Cancer Research (Cleveland Clinic) Posdoctoral Position – Prostate Cancer Research (Louisiana State University Health Sciences Center) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities) Research Fellow – Prostate Cancer (Sechenov University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|